Literature DB >> 21115306

The diagnostic dilemma of pathological appearance and performance enhancing drug use.

Tom Hildebrandt1, Justine K Lai, James W Langenbucher, Melanie Schneider, Rachel Yehuda, Donald W Pfaff.   

Abstract

Appearance and performance enhancing drug (APED) use includes the use of a range of pharmacologically distinct substances and concurrent investment in outward appearance or achievement, dietary control, and frequent exercise. A number of existing reviews and conceptual papers have defined pathological forms of APED use within the APED class of anabolic-androgenic steroids (AASs) and using the framework of AAS dependence. We review published data on APED use including human studies of AAS users and identified three defining phenomenological features associated with increased health risk and pathology. These features included (1) polypharmacy or the concurrent use of several pharmacologically distinct substances used to change outward appearance or increase likelihood of personal achievement; (2) significant body image disturbance; (3) rigid practices and preoccupations with diet and exercise. Investigations into the latent structure of APED use suggest these features cluster together in a homogenous group of APED users who have the highest health risk and most psychopathology. These features are discussed in the context of AAS dependence and problems with defining classic tolerance-withdrawal symptoms among APED users. Suggestions for a resolution and outline for future research needed to determine the best system for identifying and diagnosing pathological APED use are discussed.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115306      PMCID: PMC3039045          DOI: 10.1016/j.drugalcdep.2010.09.018

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  126 in total

Review 1.  Nonvitamin, nonmineral dietary supplements: issues and findings from NHANES III.

Authors:  K L Radimer; A F Subar; F E Thompson
Journal:  J Am Diet Assoc       Date:  2000-04

2.  Medication use by athletes at the Athens 2004 Summer Olympic Games.

Authors:  Christina Tsitsimpikou; Athanasios Tsiokanos; Konstantinos Tsarouhas; Patrick Schamasch; Kenneth D Fitch; Dimitrios Valasiadis; Athanasios Jamurtas
Journal:  Clin J Sport Med       Date:  2009-01       Impact factor: 3.638

3.  Anabolic steroid-induced hypogonadotropic hypogonadism.

Authors:  J P Jarow; L I Lipshultz
Journal:  Am J Sports Med       Date:  1990 Jul-Aug       Impact factor: 6.202

Review 4.  Alcohol dependence: provisional description of a clinical syndrome.

Authors:  G Edwards; M M Gross
Journal:  Br Med J       Date:  1976-05-01

Review 5.  Substance use disorders: Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and International Classification of Diseases, tenth edition (ICD-10).

Authors:  Deborah Hasin; Mark L Hatzenbuehler; Katherine Keyes; Elizabeth Ogburn
Journal:  Addiction       Date:  2006-09       Impact factor: 6.526

Review 6.  The cardiac toxicity of anabolic steroids.

Authors:  M L Sullivan; C M Martinez; P Gennis; E J Gallagher
Journal:  Prog Cardiovasc Dis       Date:  1998 Jul-Aug       Impact factor: 8.194

7.  Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?

Authors:  A Urhausen; T Albers; W Kindermann
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

Review 8.  A biopsychosocial model of disordered eating and the pursuit of muscularity in adolescent boys.

Authors:  Lina A Ricciardelli; Marita P McCabe
Journal:  Psychol Bull       Date:  2004-03       Impact factor: 17.737

9.  Anabolic steroid users' attitudes towards physicians.

Authors:  Harrison G Pope; Gen Kanayama; Martin Ionescu-Pioggia; James I Hudson
Journal:  Addiction       Date:  2004-09       Impact factor: 6.526

10.  Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids.

Authors:  R D Dickerman; F Schaller; I Prather; W J McConathy
Journal:  Cardiology       Date:  1995       Impact factor: 1.869

View more
  14 in total

1.  Development and validation of the appearance and performance enhancing drug use schedule.

Authors:  Tom Hildebrandt; James W Langenbucher; Justine Karmin Lai; Katharine L Loeb; Eric Hollander
Journal:  Addict Behav       Date:  2011-05-11       Impact factor: 3.913

Review 2.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

3.  The influence of age of onset and acute anabolic steroid exposure on cognitive performance, impulsivity, and aggression in men.

Authors:  Tom Hildebrandt; James W Langenbucher; Adrianne Flores; Seth Harty; Heather A Berlin; Heather Berlin
Journal:  Psychol Addict Behav       Date:  2014-05-19

4.  The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates.

Authors:  Harrison G Pope; Gen Kanayama; Alison Athey; Erin Ryan; James I Hudson; Aaron Baggish
Journal:  Am J Addict       Date:  2013-09-20

Review 5.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 6.  Illicit use of androgens and other hormones: recent advances.

Authors:  Gen Kanayama; Harrison G Pope
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-06       Impact factor: 3.243

7.  Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem.

Authors:  Gen Kanayama; James I Hudson; James DeLuca; Stephanie Isaacs; Aaron Baggish; Rory Weiner; Shalender Bhasin; Harrison G Pope
Journal:  Addiction       Date:  2015-02-25       Impact factor: 6.526

8.  Fitness supplements as a gateway substance for anabolic-androgenic steroid use.

Authors:  Tom Hildebrandt; Seth Harty; James W Langenbucher
Journal:  Psychol Addict Behav       Date:  2012-04-09

9.  Psychosocial correlates of gap time to anabolic-androgenic steroid use.

Authors:  Patrycja Klimek; Tom Hildebrandt
Journal:  Int J Eat Disord       Date:  2018-03-15       Impact factor: 4.861

10.  Cognitive deficits in long-term anabolic-androgenic steroid users.

Authors:  Gen Kanayama; Joseph Kean; James I Hudson; Harrison G Pope
Journal:  Drug Alcohol Depend       Date:  2012-12-14       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.